Note to our followers: Due to a lack of sufficient funding, HealthNewsReview.org will cease daily publication of new content at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. If you wish to donate, your gift might help keep the site available to the public for a few more years, by defraying costs of web hosting and maintenance. All of our 6,000+ published articles contain lessons to help people improve their critical thinking about health care. Read more about our change in status. And here's how to make a donation.
Read Original Release

Recap of small study on schizophrenia diagnostic device offers false hope

Promise of faster, more accessible schizophrenia diagnosis, Rutgers study shows

Our Review Summary

This news release describes a 50-person study that tested whether a hand-held device that measures electrical activity in the retina can be used to diagnose schizophrenia. The study was published in the Journal of Abnormal Psychology. The news release addresses the availability of the device and doesn’t engage in disease-mongering. However, it doesn’t talk about costs or study limitations, and the lead offers false hope by stating that a device “common in optometrists’ offices may hold the key to faster diagnosis of schizophrenia.”

 

Why This Matters

Schizophrenia is a chronic mental disorder that tends to emerge during teen and young adult years and can create disabling symptoms. Medications and talk therapy can help. However, treatment can be delayed because it’s difficult to diagnose. Symptoms can overlap with those of other conditions. Also, in teens, early signs such as flagging grades and irritability are common in adolescents.

Criteria

Does the news release adequately discuss the costs of the intervention?

Not Satisfactory

There was no discussion of the cost of this device (or the cost of a test using the device). One news release put the cost at “less than $15,000.”

Does the news release adequately quantify the benefits of the treatment/test/product/procedure?

Not Satisfactory

The news release stated the results “show the device accurately indicated reduced electrical activity in the retina in multiple cell layers in the participants who had schizophrenia, including in cell types that had not been studied before in this disorder.”

Presumably this meant that all of the patients with schizophrenia were identified, but there are no numbers. Also, the news release didn’t explain whether the device accurately ruled out schizophrenia in those who didn’t have it.

The news release and scientific article both referred to group (averaged) data, which is distinct from individual diagnosis.

Does the news release adequately explain/quantify the harms of the intervention?

Not Satisfactory

What’s known about the safety of this device? And what about the chances of false positives or false negatives? The news release didn’t say. It only quoted a researcher stating the test was performed to be “as noninvasive and quick as possible.”

Does the news release seem to grasp the quality of the evidence?

Not Satisfactory

There was no mention of limitations of this study, such as the small number of participants. It also wasn’t clear whether the study was blinded; presumably at least the study participants if not the researchers taking the measurements knew their status.

A study to show the diagnostic usefulness of the device would require a much larger sample of mostly younger people, positive and negative predictive values, and involve patients with other conditions such as mood and drug abuse disorders.

Does the news release commit disease-mongering?

Not Applicable

No disease mongering here. But the release doesn’t provide much context about the disease other than a quote from the lead researcher: “Schizophrenia is a devastating disorder, probably the most disabling disorder long term. Although we know quite a bit about it, it’s still not that well understood.”

The prevalence of schizophrenia and related psychotic disorders in the U.S. is estimated at 0.25 percent to 0.64 percent of the US population.

Does the news release identify funding sources & disclose conflicts of interest?

Not Satisfactory

The news release did not mention who funded this study, and it which wasn’t mentioned in the study itself, as far as we could tell. The release also didn’t mention that one of the authors is employed by LKC Technologies, which makes these devices.

Does the news release compare the new approach with existing alternatives?

Not Satisfactory

There was no discussion of how schizophrenia is diagnosed currently, which involves a checklist of symptoms such as delusions, incoherent speech, hallucinations, hearing voices, cognitive problems, or a flattening of emotions that hang on for months. How accurate is that method, and how much does it cost?

Does the news release establish the availability of the treatment/test/product/procedure?

Satisfactory

The release said the device is “common in optometrists’ offices.”

Does the news release establish the true novelty of the approach?

Not Satisfactory

The news release said was this is the first time a portable device was used for these tests.

The news release also notes that, “Looking at biomarkers in the eye as a way to understand psychiatric disorder is a new field of study,” but the journal article cites studies as far back as 1999. So not so new.

Does the news release include unjustifiable, sensational language, including in the quotes of researchers?

Not Satisfactory

The lead sentence oversold this study, indicating that it showed how a common device “may hold the key to faster diagnosis of schizophrenia, predicting relapse and symptom severity and assessing treatment effectiveness.”

The news release headline also over-reaches. A better headline might have been the sub-title: “Researchers explore eye function in schizophrenia as a window into the brain.”

But further down the news release quoted a researcher stating that the study “should help generate further research” into developing a test clinicians can use to diagnose, treat and monitor people with schizophrenia.

And at the end a quote — from lead author Docia Demmin — tempered the assertion by stating “it’s too soon to call this a diagnostic tool.”

Total Score: 1 of 9 Satisfactory

Comments

We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.

We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.